[Drug safety. Notes regarding drug surveillance].
Moreno Alvarez
P J
PJ
Servicio de Farmacia, Hospital Virgen del Puerto, Plasencia, Cáceres. pmorenoal@sefh.es
Madurga Sanz
M
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000927:Anticonvulsants / Q000009:adverse effects; D000998:Antiviral Agents / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects; D002219:Carbamates / Q000009:adverse effects; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005334:Fever / Q000139:chemically induced; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives*; D015248:Gemfibrozil / Q000009:adverse effects; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007007:Hypohidrosis / Q000139:chemically induced; D000960:Hypolipidemic Agents / Q000009:adverse effects; D010880:Piperidines / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D012202:Reye Syndrome / Q000139:chemically induced; D000077236:Topiramate; D017211:Treatment Failure
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D000998:Antiviral Agents; D002219:Carbamates; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D010880:Piperidines; D000077236:Topiramate; D005632:Fructose; C072379:repaglinide; D015248:Gemfibrozil; D001241:Aspirin